Singapore, Jan 25, 2010: Caprion Proteomics, a provider of proteomics-based service to the pharma and biotech industries, has acquired the biomarker services unit of PPD.

Both the companeis refused to disclose the financial terms.

Caprion said the the acquisition further strengthens Caprion's market leadership position in the area of proteomics biomarker services and will also broaden its client portfolio and revenue base.

Caprion will perform existing contractual obligations acquired as part of this acquisition from both Caprion's facilities in Montreal and from a new facility in Menlo Park that will operate under the name Caprion Proteomics.

"We are very pleased to add the solid scientific capabilities, experience and customer relationships of PPD's biomarker unit to Caprion's rapidly growing biomarker services business," said Martin LeBlanc, President and CEO of Caprion. "By acquiring this business, we will expand our capacity and be able to better meet the growing biomarker needs of our current and future clients."

"This acquisition will be immediately accretive for Caprion both from a financial and strategic standpoint," said Adam Dolder, Managing Director at Great Point Partners, LP, Caprion's majority shareholder. "It further positions the Company for continued growth and solidifies its market leadership position in the biomarker space."